Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304590 · ClinicalTrials.gov registry record · Phase 2
Study of XL999 in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Symphony Evolution.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00304590: Clinical Trial Phase 2 study, sponsored by Symphony Evolution.
NCT00304590 is a Phase 2 study that was terminated before completion, run by Symphony Evolution. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304590, a Phase 2 study, was terminated before completion, sponsored by Symphony Evolution.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Interventions
- DRUG XL999
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Why NCT00304590 stopped before completion
NCT00304590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which XL999 is the first listed.
NCT00304590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00304590 about?
NCT00304590 is a clinical study titled "Study of XL999 in Patients With Multiple Myeloma". This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be invol...
What is the current status of trial NCT00304590?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2006-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00304590?
The interventions under investigation include: XL999 (DRUG).
Who is sponsoring clinical trial NCT00304590?
This trial is sponsored by Symphony Evolution, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00304590's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia